August Bioservices, LLC, a CDMO providing drug discovery, development, and pharmaceutical manufacturing services, closed a $23.6 million Series A extension, led by Polaris Partners. The proceeds will go toward expanding August’s manufacturing capacity and capabilities to advance the technology platforms needed to support production of sterile injectable medications.
 
As part of the financing, Brian Chee, Managing Partner of Polaris Partners, joined the August Bioservices’ board as a Director.
 
August Bioservices, headquartered in Nashville, TN, partners with biopharmaceutical companies to provide services to help to accelerate the advancement of novel therapeutics. August’s service portfolio includes cGMP non-sterile and bulk manufacturing, aseptic fill and finish, labeling and related services. The company also provides drug formulation, process design and scale-up, analytical and stability testing, and research services that feature target validation, characterization and assay development, protein engineering and cell-line development.
 
In November 2020, August announced a planned $64.7 million investment to expand its Nashville manufacturing operations, which will add 180 jobs over five years. The first expansion project, which will focus on renovating August’s existing facility, includes the addition of development and manufacturing capabilities for liquid and lyophilized vials, prefilled syringes, IV bags and terminal sterilization. This renovation is expected to be completed in late 2021. The second expansion project will add a new state-of-the-art, high-speed manufacturing facility, adjacent to the existing building, which will create one contiguous campus for drug discovery, development and manufacturing in Nashville.
 
“We are delighted to welcome Polaris Partners to the August Bioservices team,” commented Jenn Adams, CEO of August Bioservices. “Polaris shares our focus on offering the highest quality research, development and manufacturing services to our customers as they work to provide lifesaving medications to patients who need them. We look forward to a long and productive partnership as we deploy resources toward serving the global biopharmaceutical industry with increasing impact.”